Taking a novel approach to drug development

Lantern’s drug development approach is innovative. From the novel small molecule compounds in our portfolio, to our targeted, rare patient populations who will benefit from these drugs, our pending and issued patent portfolio reflects our unique precision oncology focus.

Pending Patent Applications

General Application

Next Generation Illudins

Patent Title

Illudin Analogs, Used Thereof, and Methods for Synthesizing the Same

Patent Summary

This application covers illudin derivatives or analogs, intermediates, preparation methods, pharmaceutical compositions and uses thereof.  A new and potentially more potent illudin is disclosed in this application.  A more effective and efficient manufacturing scheme is also disclosed in this application.

Patent No./Application No.

62726914

Countries

US and other countries TBD

Priority of Filing Date

9/4/18

General Application

RADR Applications

Patent Title

Anticancer Drug Sensitivity-Determining Markers

Patent Summary

This application covers a marker for use in determination of the sensitivity of a cancer patient to an anti-cancer agent (e.g., illudins) to be administered thereto, which marker can determine whether or not the cancer of the patient has a therapeutic response to the anti-cancer agent, and to application of the marker.  Also included is a method for determining sensitivity of a subject having cancer to a illudin-based anti-cancer agent, the method includes measuring a level or presence of PTGR1 and at least one other gene.

Patent No./Application No.

62745382

Countries

US and other countries TBD

Priority of Filing Date

10/14/18

General Application

Female Non-Smokers with Non-Small Cell Lung Cancer Treatment

Patent Title

Method for Treating Female Non Smokers with Non-Small Cell Lung Cancer

Patent Summary

his application covers a method for increasing survival time in a female patient with non-small cell lung carcinoma or non-small cell lung carcinoma in which 2,2′-dithio-bis-ethane sulfonate or salt is administered in a therapeutically effective amount to the patient with non-small cell lung carcinoma.

Patent No./Application No.

62815762

Countries

US and other countries TBD

Priority of Filing Date

3/8/19

General Application

PTGR1 Application

Patent Title

PTGR1 Sensitivity and Acylfulvene Efficacy in Cancer Treatments

Patent Summary

This application covers methods and materials for identifying and treating candidate patients with acylfulvenes.

Patent No./Application No.

62852913

Countries

US and other countries TBD

Priority of Filing Date

5/24/19

General Application

Tavocept®

Patent Title

Contemporaneous, Multiple Protein-Targeted Therapeutic Modification and/or Modulation of Disease by Administration of Sulfur-Containing, Amino Acid-Specific Small Molecules

Patent Summary

A method for the contemporaneous, heterogeneously-oriented metabolic modification and/or modulation of the expression level of multiple target molecules; wherein any combination of target molecules is selected from the group consisting of: anaplastic lymphoma kinase (ALK), mesenchymal epithelial transition (MET) kinase, the receptor tyrosine kinase (ROS1), epidermal growth factor receptor (EGFR), peroxiredoxin (Prx), excision repair cross-complementing protein 1 (ERCC1), insulin growth factor 1 receptor (IGF1R), ribonucleotide reductase, tubulin, farnesyltransferase, and other target molecules possessing a similar active site or structural motif.

Patent No./Application No.

14455855

Countries

US

Priority of Filing Date

8/8/14

General Application

Tavocept®

Patent Title

Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds

Patent Summary

This application covers a method for (i) increasing patient survival time; (ii) promoting the arrest or retardation of tumor progression; (iii) concomitantly maintaining or increasing the quality of life in a cancer patient; and/or (iv) potentiating the cytotoxic/cytostatic effects of a chemotherapy agent or agents used to treat a patient suffering from cancer.

Patent No./Application No.

14675607 (Issue Fee Paid)

Countries

US

Priority of Filing Date

9/16/10

Issued Patents

General Application

Tavocept®

Patent Title

Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds

Patent Summary

This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions

Patent No./Application No.

US9023805

Countries

US

Priority of Filing Date

9/16/10

General Application

Tavocept®

Patent Title

Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions

Patent Summary

This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions

Patent No./Application No.

US9320760

Countries

Australia, Canada, China, Denmark, France, Germany, Japan, Netherlands, Sweden, Switzerland, UK, and US

Priority of Filing Date

7/15/08

General Application

Tavocept®

Patent Title

Medicinal Disulfide Salts

Patent Summary

This patent is directed to various medicinal disulfide salts

Patent No./Application No.

US7282602

Countries

Canada, Japan, Mexico, and US

Priority of Filing Date

9/21/04

General Application

Tavocept®

Patent Title

Treatment Methods and Compositions for Lung Cancer, Adenocarcinoma, and Other Medical Conditions

Patent Summary

This patent is directed to an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions

Patent No./Application No.

US9320760

Countries

Australia, Canada, China, Denmark, France, Germany, Japan, Netherlands, Sweden, Switzerland, UK, and US

Priority of Filing Date

7/15/08

General Application

Tavocept®

Patent Title

Chemoprotective Methods and Compositions

Patent Summary

Compositions and methods for reducing, preventing, mitigating, and/or delaying the onset of, attenuating the severity of, and/or hastening the resolution of, for example, one or more chemotherapy-associated toxicities in a subject receiving one or more chemotherapeutic agents.

Patent No./Application No.

CA2648945

Countries

Australia, Canada, China, Denmark, France, Germany, Hungary, Ireland, Italy, Japan, Netherlands,  Sweden, Switzerland, and UK

Priority of Filing Date

12/13/06

General Application

Tavocept®

Patent Title

Process for Synthesizing Disulfides

Patent Summary

This patent discloses a process for producing a substantially pure disulfide , such as disodium 2,2_-dithiobis ethane sulfonate, by an efficient procedure from available, relatively inexpensive raw materials.

Patent No./Application No.

US7053240

Countries

Australia, Canada, China

Priority of Filing Date

12/17/04

General Application

Tavocept®

Patent Title

Method of Treating Patients Undergoing Kidney Dialysis

Patent Summary

This invention relates to a method of treating patients who are receiving dialysis treatments. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.

Patent No./Application No.

US7235589

Countries

France, UK and US

Priority of Filing Date

9/21/05

General Application

Tavocept®

Patent Title

Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents

Patent Summary

The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.

Patent No./Application No.

US Patent Nos. 7829540, 7829539, 7829117, 7829538 & 7235589

Countries

France, UK and US

Priority of Filing Date

11/14/07

General Application

Tavocept®

Patent Title

Method For Preparing Disodium 2,2′-Dithiobis(Ethanesulfonate

Patent Summary

Method For Preparing Disodium 2,2′-Dithiobis(Ethanesulfonate

Patent No./Application No.

US6936733

Countries

Australia, Belgium, France, Germany, Ireland, Italy, Japan, Sweden, Switzerland, UK and US

Priority of Filing Date

7/17/01

General Application

Tavocept®

Patent Title

Drugs for Prophylaxis or Mitigation of Taxane-Induced Neuropathies

Patent Summary

This Patent covering treating taxane neuropathy with 2,2_-dithiobis ethane sulfonate

Patent No./Application No.

US8710095

Countries

Australia,  France, Germany,  Japan, Spain, Sweden, Switzerland,  UK and US

Priority of Filing Date

4/30/02

General Application

Tavocept®

Patent Title

Process for Synthesizing Pharmaceutically Active Disulfide Salts

Patent Summary

This patent covers a process for synthesizing pharmaceutically active  disulfide or thiol-containing compound

Patent No./Application No.

US6504049

Countries

Australia, Canada, Denmark, France, Germany,  Ireland, Italy, Japan, Netherlands, Spain, Sweden, Switzerland, UK and US

Priority of Filing Date

5/30/02

General Application

Other Applications

Patent Title

Method for Treating Patients for Radiation Exposures

Patent Summary

This patent covers treating patents for radiation exposure with  disulfide or thiol-containing compound.

Patent No./Application No.

US7176192

Countries

US

Priority of Filing Date

10/26/01

General Application

Tavocept®

Patent Title

Method for Treating Cancer Having Greater Efficacy and Reduced Adverse Effects

Patent Summary

This patent covers reducing side effects with  disulfide or thiol-containing compound .

Patent No./Application No.

US6596320

Countries

US

Priority of Filing Date

1/11/02

General Application

Tavocept®

Patent Title

Methods and Formulations for Reducing Toxicity Associated with Diabetes Treatments

Patent Summary

This patent covers reducing side effects from diabetes treatments with  disulfide or thiol-containing compound .

Patent No./Application No.

US6468963

Countries

US

Priority of Filing Date

5/1/00

General Application

Tavocept®

Patent Title

Method of Inhibiting Angiogenesis

Patent Summary

This patent covers inhibiting angiogenesis with  disulfide salts.

Patent No./Application No.

US6255355

Countries

US

Priority of Filing Date

1/6/01

General Application

Tavocept®

Patent Title

Method of Treating Acetaminophen Overdose

Patent Summary

This patent covers treating acetaminophen overdose with disulfide or thiol-containing compound .

Patent No./Application No.

US6225295

Countries

US

Priority of Filing Date

9/27/00

General Application

Tavocept®

Patent Title

Method of Treating Atherosclerosis and Complications Resulting Therefrom.

Patent Summary

Method of Treating Atherosclerosis and Complications using  disulfide or thiol-containing compound.

Patent No./Application No.

US6525037

Countries

US

Priority of Filing Date

2/25/00

General Application

Tavocept®

Patent Title

Method of Treating Diabetic Nephropathy

Patent Summary

Method of Treating Diabetic Nephropathy with  disulfide or thiol-containing compound

Patent No./Application No.

US6031006 & US6100247

Countries

US

Priority of Filing Date

10/21/99

General Application

Tavocept®

Patent Title

Method for Reducing Development of Free Radical Induced Malignancies

Patent Summary

Method for Reducing Development of Free Radical Induced Malignancies

Patent No./Application No.

US6143796

Countries

US

Priority of Filing Date

9/2/99

General Application

Tavocept®

Patent Title

Anti-Cancer Activity Augmentation Compounds and Formulations & Methods of Use Thereof

Patent Summary

Methods for augmentation of anti-cancer activity

Patent No./Application No.

China ZL200780017354

Countries

China, Australia

Priority of Filing Date

3/16/07

General Application

Tavocept®

Patent Title

Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents

Patent Summary

The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.

Patent No./Application No.

US7176192

Countries

Australia

Priority of Filing Date

10/26/01

General Application

Tavocept®

Patent Title

Compounds and Methods for Reducing Undesired Toxicity of Chemotherapeutic Agents

Patent Summary

The compositions of matter are amino acid and peptide heteroconjugated disulfides of 2-mercaptoethane sulfonate sodium.

Patent No./Application No.

US7176192

Countries

Australia

Priority of Filing Date

10/26/01

General Application

Irofulven

Patent Title

Illudin Analogs Useful as Anticancer Agents

Patent Summary

Acylfulvene analogs, which inhibit tumor growth, especially solid tumor growth, and which have an adequate therapeutic index to be effective for in vivo treatment

Patent No./Application No.

US7655695

Countries

EP1909783B1 (Germany, France, and Great Britain), JP4989648 (US is Priority Application)

Priority of Filing Date

2/2/10

General Application

Irofulven

Patent Title

Antitumor Agents

Patent Summary

Various Acylfulvene analogs with various R groups thereon

Patent No./Application No.

US7141603

Countries

US Only

Priority of Filing Date

11/28/06

Let’s start a conversation about the future of drug development.

We are a biotech pharma at the intersection of Artificial Intelligence, genomics, and oncology drug development.

Contact Us